Nuwellis Inc. Reports Q1 2025: Revenue Rises 3%, Net Loss Narrows to $3M, EPS Improves to -$0.69

Reuters
13 May
Nuwellis Inc. Reports Q1 2025: Revenue Rises 3%, Net Loss Narrows to $3M, EPS Improves to -$0.69

Nuwellis, Inc. reported its financial results for the first quarter of 2025, showing a revenue of $1.9 million, which marks a 3% increase compared to the same period in 2024. This growth was attributed to a 4% rise in consumables utilization and higher U.S. console sales, partially offset by a decline in international sales. However, the company's gross margin decreased to 56.0% from 64.1% in the prior-year quarter, primarily due to unfavorable manufacturing variances and lower fixed overhead absorption. The net loss attributable to common shareholders was $3.0 million, compared to a net loss of $3.8 million in the same period in 2024. Operating loss improved to $3.1 million, down from $4.7 million in the previous year's first quarter. Total operating expenses for the quarter were reduced by 31% to $4.1 million, driven by a significant decrease in selling, general, and administrative expenses as well as research and development expenses. Nuwellis highlighted strategic advancements, including growth in customer categories and strengthened foundations for Aquadex therapy adoption. The company is well-positioned to expand both inpatient and outpatient environments in 2025, with higher CMS reimbursement and strong pediatric performance contributing to its optimism. As of March 31, 2025, Nuwellis held $2.6 million in cash and cash equivalents and remained debt-free.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuwellis Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-25-018543), on May 13, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10